M&A Deal Summary |
|
|---|---|
| Date | 2025-11-06 |
| Target | Baergic Bio |
| Sector | Life Science |
| Buyer(s) | Axsome |
| Sellers(s) | Avenue Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 712 |
| Revenue | 386M USD (2024) |
Axsome is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through the development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. Axsome was founded in 2012 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-03-28 |
Jazz Pharmaceuticals - Sunosi
Dublin, Ireland Jazz Pharmaceuticals' Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). |
Buy | $53M |
| Category | Company |
|---|---|
| Founded | 2015 |
| Sector | Life Science |
Avenue Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of therapies for neurologic diseases. The Company was founded in 2015 and is headquartered in the Bay Harbor Islands, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
